作者:Brijesh Kumar Srivastava、Mukul R. Jain、Manish Solanki、Rina Soni、Darshan Valani、Sunil Gupta、Bhupendra Mishra、Vijay Takale、Prashant Kapadnis、Harilal Patel
DOI:10.1016/j.ejmech.2007.05.003
日期:2008.4
Design and synthesis of novel piperazinylaryloxazolidinones possessing heteroaryl groups are described and their in vitro antibacterial activities have been evaluated by MIC assay. Compounds (S)-N-[3-3-fluoro-4-[4-[3-(5-nitrofuran-2-yl)-acryloyl]-piperazin-1-yl]-phenyl}- 2-oxo-oxazolidin-5-yl-methyl] acetamide (6o), (S)-N-[3-3-fluoro-4-[4-[3-(5-nitrothien-2-yl)-acryloyl]-piperazin-1-yl]-phenyl}-
描述和新型具有杂芳基的哌嗪基芳基恶唑烷酮的设计和合成,并通过MIC分析评估了它们的体外抗菌活性。化合物(S)-N- [3- 3-氟-4- [4- [3-(5-硝基呋喃-2-基)-丙烯酰基]-哌嗪-1-基]-苯基} -2-氧代-恶唑烷-5-基-甲基]乙酰胺(6o),(S)-N- [3- 3-氟-4- [4- [3-(5-硝基噻吩-2-基)-丙烯酰基]-哌嗪- 1-基]-苯基} -2-氧-恶唑烷-5-基-甲基]乙酰胺(6p)和(S)-N- [3- 3-氟-4- [4- [3] -(5-硝基呋喃-2-基)-丙烯酰基]-哌嗪-1-基]-苯基}-2-氧代-恶唑烷丁-5-基-甲基]乙酰胺(9)具有优于利奈唑胺的抗菌活性,并且对耐利奈唑胺的金黄色葡萄球菌菌株。